Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

NCT04756765 PHASE2 WITHDRAWN

This purpose of this study is to test if talazoparib is safe and evaluate its response to advanced breast cancer associated with mutation of gene called PALB.

Details

Lead sponsor	Stanford University
Phase	PHASE2
Status	WITHDRAWN
Start date	Thu Feb 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Dec 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Breast Cancer
• Advanced Breast Cancer

Interventions

• Talazoparib Tosylate

Countries

United States